You have 9 free searches left this month | for more free features.

TTI-101

Showing 1 - 25 of 698

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Pancreatic Cancer Trial in Aurora (TTI-101)

Not yet recruiting
  • Pancreatic Cancer
  • TTI-101
  • Aurora, Colorado
    University of Colorado
Nov 30, 2023

Idiopathic Pulmonary Fibrosis Trial (TTI-101, Placebo)

Not yet recruiting
  • Idiopathic Pulmonary Fibrosis
  • TTI-101
  • Placebo
  • (no location specified)
Jan 3, 2023

Squamous Cell Carcinoma of Head and Neck Trial in Houston (Control Group, TTI-101)

Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Control Group
  • TTI-101
  • Houston, Texas
    M D Anderson Cancer Centerl
Apr 25, 2023

Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

Recruiting
  • Breast Cancer
  • TTI-101
  • +2 more
  • Saint Louis, Missouri
  • +2 more
Jan 12, 2023

Head and Neck Squamous Cell Carcinoma Trial (TTI-101, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Dec 20, 2022

Hepatocellular Carcinoma Trial (TTI-101, Pembrolizumab, Atezolizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • TTI-101
  • +3 more
  • (no location specified)
Jun 30, 2022

Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer Trial in Atlanta, Houston, San Antonio

Recruiting
  • Breast Cancer
  • +7 more
  • TTI-101
  • Atlanta, Georgia
  • +2 more
Jun 13, 2022

Multiple Myeloma Trial in United States (TTI-622, Daratumumab Hyaluronidase-fihj)

Recruiting
  • Multiple Myeloma
  • TTI-622
  • Daratumumab Hyaluronidase-fihj
  • Basking Ridge, New Jersey
  • +6 more
Dec 8, 2022

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Lymphoma, Multiple Myeloma Trial in Nagoya, Koto, Yamagata (TTI-622)

Recruiting
  • Lymphoma
  • Multiple Myeloma
  • Nagoya, Aichi, Japan
  • +2 more
Jan 20, 2023

COVID-19, COVID-19 Acute Respiratory Distress Syndrome Trial (TTI-0102, Placebo)

Not yet recruiting
  • COVID-19
  • COVID-19 Acute Respiratory Distress Syndrome
  • (no location specified)
May 13, 2022

Chronic Hepatitis b Trial in Auckland (AB-101, Placebo, Nucleos(t)ide Analogue)

Not yet recruiting
  • Chronic Hepatitis b
  • Auckland, New Zealand
    New Zealand Clinical Research Auckland
Jul 26, 2023

Leiomyosarcoma Trial in United States (TTI-621, Doxorubicin)

Recruiting
  • Leiomyosarcoma
  • Santa Monica, California
  • +26 more
Jul 26, 2022

Nasopharyngeal Carcinoma Trial in Wuhan (KSD-101)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • KSD-101
  • Wuhan, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 19, 2023

Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in United States (FT596, Cyclophosphamide, Fludarabine)

Recruiting
  • Lymphoma, B-Cell
  • Chronic Lymphocytic Leukemia
  • Chicago, Illinois
  • +8 more
Jun 21, 2022

Solid Tumor Trial in China (BPB-101)

Not yet recruiting
  • Solid Tumor
  • Guangzhou, Guangdong, China
  • +3 more
May 11, 2023

Frontotemporal Dementia, FTD, FTD-GRN Trial in Poland, Spain (Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101)

Recruiting
  • Frontotemporal Dementia
  • +3 more
  • Intrathalamic AAV.PGRN administration
  • Intrathalamic AVB-101
  • Katowice, Poland
  • +3 more
Oct 6, 2023

Nonalcoholic Fatty Liver Disease Trial in Jerusalem (Anti-human CCL24 mAb (CM-101) - Part One, Anti-human CCL24 mAb (CM-101) -

Completed
  • Nonalcoholic Fatty Liver Disease
  • Anti-human CCL24 monoclonal antibody (CM-101) - Part One
  • +3 more
  • Jerusalem, Israel
    Hadassah University Hospital - Ein Kerem
Sep 13, 2023

Cancer Trial (Antibody-Drug Conjugate)

Not yet recruiting
  • Cancer
  • Antibody-Drug Conjugate
  • (no location specified)
Aug 23, 2023

Community-acquired Pneumonia, Bacterial Pneumonia Trial in Cincinnati (CMTX-101, Placebo)

Recruiting
  • Community-acquired Pneumonia
  • Bacterial Pneumonia
  • Cincinnati, Ohio
    Medpace Clinical Pharmacology Unit
Jan 20, 2023

Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB Trial in Redwood City, Worcester (EB-101 Surgical

Not yet recruiting
  • Epidermolysis Bullosa
  • +2 more
  • EB-101 Surgical application of RDEB wounds
  • Redwood City, California
  • +1 more
Feb 13, 2023

NSCLC, HNSCC, Melanoma Trial (CJRB-101, Pembrolizumab injection)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Jun 1, 2023

Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis Trial (KYV-101, Cyclophosphamide,

Not yet recruiting
  • Idiopathic Inflammatory Myopathies
  • +3 more
  • (no location specified)
Nov 21, 2023

Metastatic Lung Cancer Trial in France (InvisionFirstĀ® molecular panel)

Active, not recruiting
  • Metastatic Lung Cancer
  • InvisionFirstĀ® molecular panel
  • Bayeux, France
  • +15 more
Aug 22, 2022

Orthostatic Hypotension Trial in Newcastle Upon Tyne (ISO-101)

Not yet recruiting
  • Orthostatic Hypotension
  • ISO-101
  • Newcastle Upon Tyne, United Kingdom
    Falls and Syncope Service, Older People's Medicine, The Newcastl
Sep 8, 2023